- Research Article
- Open Access
United States Health Policies and Late-stage Breast and colorectal cancer diagnosis: Why such disparities by age?
Health Economics Review volume 5, Article number: 20 (2015)
Colorectal and breast cancers are the second most common causes of cancer deaths in the US. Population cancer screening rates are suboptimal and many cancers are diagnosed at an advanced stage, which results in increased morbidity and mortality. Younger populations are more likely to be diagnosed at a later stage, and this age disparity is not well understood. We examine the associations between late-stage breast cancer (BC) and colorectal cancer (CRC) diagnoses and multilevel factors, focusing on individual state regulations of insurance and health practitioners, and interactions between such policies and age. We expect state-level regulations are significant predictors of the rates of late-stage diagnosis among younger adults.
We included adults of all ages, with BC or CRC diagnosed between 2004 –2009, obtained from a newly available cancer population database covering 98 % of all known new cancer cases. We included personal characteristics, linked with a set of county and state-level predictors based on residence. We applied multilevel models to robustly examine differences in risk of late-stage cancer diagnosis across age groups (defined as age 65+ or < 65), focusing specifically on the effects of state regulatory factors and their interactions with age.
Late stage BC diagnoses range from 24 %-36 %, while CRC diagnoses range from 54 %-60 % of newly diagnosed BC or CRC cases across states. After controlling statistically for many confounding factors at three levels, age < 65 is the largest person-level predictor for CRC, while black race is the largest predictor for BC. State regulations of health markets exhibit significant interactions with age groups.
The state regulatory climate is an important predictor of late-stage BC and CRC diagnoses, especially among people younger than Medicare eligible age (65). State regulations can enhance the climate of access for younger, less well-insured or uninsured persons who fall outside normative screening guidelines.
Colorectal cancer (CRC) is the third most common cancer in men and women, and is the second leading cause of cancer deaths in the United States. The risk of CRC begins to increase after the age of 40 years and increases more rapidly at ages 50 to 55 years. Overall, the risk doubles with each succeeding decade, and continues to rise exponentially . The 5-year survival rate for CRC patients is about 65 %. Colorectal cancer incidence rates have been decreasing for most of the past two decades, which has largely been attributed to increases in the use of endoscopic colorectal cancer screening tests that allow the detection and removal of colorectal polyps before they progress to cancer. In contrast to the overall declines, among adults younger than 50 years, for whom screening is not routinely recommended, colorectal cancer incidence rates have been increasing each year since 1998 . By comparison, breast cancer (BC) is the most frequently diagnosed cancer in women (excluding skin cancers), and ranks second as a cause of cancer death in women. The 5-year survival rate for BC patients is 89 %. The incidence rate for female breast cancer was rising until recently, due to common use of menopausal hormone therapy, but began to decline after publication of the landmark Women’s Health Initiative study in 2002 . Since about 2003, breast cancer incidence rates have been fairly stable .
Progress has been made in the war on cancer, yet the high proportions of late-stage diagnoses remain a public health concern. The American Cancer Society states that only 39 % of CRC cases are diagnosed at an early stage , while about 80 % of BC cases are diagnosed at an early stage . Thus about 60 % of CRC and 20 % of BC are diagnosed at a late stage.
National Cancer Institute statistics show that late-stage diagnosis rates are higher among younger populations than older populations for both BC and CRC . The reasons for the disparity in late-stage cancer diagnoses by age are not well understood. Several studies have examined the predictors of stage at diagnosis for these two cancers, but have not focused on age as a predictive factor. Using SEER-Medicare data, studies have examined low SES, marital status, race or ethnicity, distance to closest provider, managed care penetration, area screening rates, or residence in a racially segregated community as predictors of late-stage diagnosis [7, 8]. Other studies which examined whole cancer populations in multiple states or regions in the US found factors such as area poverty or deprivation, lack of personal insurance, or percent uninsured in the area have associations with late-stage BC diagnosis [9, 10]. Another study found that patients privately insured or insured by Medicare plus supplemental plans had lower likelihood of being diagnosed at advanced stages of cancer than persons with other types of insurance, with highest rates among uninsured and Medicaid insureds .
In this study, we sought to gain a more comprehensive understanding of the predictors of late-stage cancer, focusing on age while controlling statistically for a large number of other factors. We use newly available data that are representative of the vast majority of the US to answer several new research questions, including: Holding constant environmental factors, do the odds of late-stage cancer diagnosis vary among people <65 and 65+, by cancer type (BC, CRC), and by state regulatory environment? Do contextual constructs in the patient’s residential environment predict their likelihood of late-stage diagnosis? Holding other factors constant statistically, are state-level regulations of health insurance or health professionals significant predictors of late-stage diagnosis?
We examined cancer cases from the United States Cancer Statistics (USCS) database, which is a population-based surveillance system of cancer registries with data representing 98 % of the U.S. population. The database was developed by a joint effort by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) to provide a single, pooled-state database of reconciled, comparable cancer information geocoded at the local level to facilitate cancer control planning and evaluation . This comprehensive database is now available inside National Centers for Health Statistics (NCHS) and Census Research Data Centers (RDCs) to qualified researchers .
Most states participate in the USCS registry data system, but not all allow use of county of residence information (Illinois, Michigan, Missouri, Ohio). Three states did not participate at all over the timeframe of this study (Kansas, Maryland, Minnesota). We excluded these 7 states and an additional state, Virginia, because data were not available until 2007. We also excluded Alaska and Hawaii, because their county designations are much different than for mainland states (each island is a county in Hawaii, and Alaska has boroughs rather than counties), and data are missing for some county-level constructs. After exclusions, this resulted in 40 states being included in the analysis over the 2004–2009 period. County level data describing contextual characteristics of communities were obtained from the RTI Spatial Impact Factor Database , which derives from numerous sources. State-level data describing insurance and practitioner regulatory environments were downloaded from the National Conference of State Legislatures databases [15, 16]. Summarizing the conceptual model: multilevel factors including person, community, and state levels of influence are predictors of the odds of cancer diagnosed at an advanced stage. Data description, sources, and brief rationale for inclusion of each covariate are provided in Table 1.
We restrict the sample to adults of all ages with a first cancer diagnosis in 2004–2009. We excluded records when BC or CRC were not the primary cancers, records with unknown cancer stage or unstaged cancer, or when diagnosis was by autopsy (<1 % of all cases). For BC we excluded males. These restrictions yielded a CRC study population of 558,568 individuals and a BC study population of 981,457 individuals.
Outcome variable. Using the SEER summary stage 2000 variable provided in the database, we coded regional or distant diagnosis as late stage, and in situ or localized diagnosis as early stage. We then created a binary indicator for each individual specifying whether their cancer was diagnosed at a late stage, or not.
County-level contextual variables. In the 40 states, there were 2,366 counties with outcomes data in the BC population and 2,361 counties with outcomes in the CRC population. We used the isolation index to measure residential segregation of minorities from whites, which has been shown to have social support or political influence effects in various studies [17, 18]. For measuring accessibility, in addition to average closest distance to provider in the county (based on 100 % FFS Medicare service flows) we included the 100 % FFS Medicare BC and CRC screening rates as robust county-level measures. We included managed care penetration to capture spillovers on area practice styles, following the recent literature which suggests there were significant managed care spillover effects on the utilization of endoscopy in 1999  and its geographic availability during 2001–2005 . Managed care penetration also captures urbanicity, so we included distance squared to help capture urbanicity and better isolate the effects of managed care. We included the percent of the under-age-65 population who had no health insurance.
Including person and area-level factors, we are better able to isolate the independent effects of age groups, defined as adults over/under age 65. The vast majority of individuals over age 65 are insured, while a lower proportion of younger individuals are insured. We do not know individuals’ insurance status, but we do control for area percent uninsured among the population aged <65. We interact age with state policy to determine whether the state policy effect is different among older and younger groups.
State Regulations of Health Markets. We included three state policy variables depicted in Figure 1, summarized in Table 1. We hypothesize that these three state regulations could plausibly affect the availability of information regarding the importance of cancer screening, or the accessibility of specialists or physicians of choice to better align patients with the best medical advice. Ward et al.  found that people with the most preferred types of insurance were less likely to be diagnosed with late-stage cancer, while uninsured and Medicaid groups were more likely diagnosed at late stage. Thus timely access to preferred physicians and specialists seems important, and state regulations that enhance this may improve access; thus the first regulatory variable – Direct Access to Specialist – is expected to enhance early-stage diagnosis outcomes. For younger populations lacking insurance or enrolled in more restrictive insurance plans, this law would help circumvent gatekeeping activities that might delay timely advice. The Ban on Financial Incentives regulation is also expected to help patients receive the best quality care, by banning the practice by insurers of rewarding physicians financially for prescribing lower cost alternative services. This is expected to be especially important for CRC outcomes, where a lower cost alternative available and prescribed during this period – the fecal occult blood test (FOBT) – does not prevent cancer by removing lesions in situ, as do the endoscopy services. For BC outcomes, this practice would perhaps inhibit prescribing MRI for women with dense breasts in place of mammogram - which is cheaper, but perhaps less effective.
As regards nurse practitioner (NP) scope of practice laws - while physicians have traditionally been the main providers of primary care services, NPs are increasingly important in this area . A systematic review of 26 studies published since 2000 found that health status, treatment practices, and prescribing behavior were consistent between NPs and physicians . In areas with greater shortages of MDs, the NPs may serve a valuable role in providing primary care services and advice to encourage cancer screening and early detection. It remains an empirical question whether these NP practice scope regulations would have greater impact on the younger or the older population groups, which we investigate here.
We used multilevel models to examine associations with late stage cancer diagnosis from predictors at person, county and state levels. We merged county-level community characteristics and state-level regulatory variables with person-level records from the USCS registry data system (Table 1).
We specify a three-level random intercept logit model for the late-stage diagnosis with patients nested in counties which are nested in states. We used a multilevel modeling (MLM) framework for estimation because we wanted to fit the regression to individuals while accounting for systematic, unexplained variation among counties and states. Ignoring the county and state level effects, when they are important, is tantamount to having omitted variables in the model, which can bias individual-level coefficient estimates. In addition, when the higher-level (e.g., county) covariates are of interest, failing to account for their structural similarity across individuals within the counties can yield biased standard errors for these county covariates, increasing their apparent statistical significance . Both of these concerns led to the adoption of the three-level random intercept logistic regression estimated here.
The three-level model, with the cross-level interactions (age group and policy) across the person- and state- levels was estimated using GLLAMM, an add-on program to STATA (http://www.gllamm.org/). This software is the only software package we know of that can efficiently estimate a three-level random-intercepts model with a binary dependent variable, many groups (2,366 counties, 40 states) and a large sample size (1/2 – 1 million observations), [23, 24]. We estimated the logistic regression model of the binary cancer stage outcome separately for each cancer type and each state policy. The models for each cancer type used identical predictors, except CRC included an indicator to differentiate males and females.
Sample statistics, Table 1: For CRC, 54 % of cases have late stage diagnosis while for BC, 31 % of cases have late stage diagnosis. About half of the CRC sample are female. In both CRC and BC samples, the majority are white. The majority of the BC sample are younger than age 65 (62 %) whereas the opposite is true for the CRC sample (42 % younger than age 65).
Estimation results, Table 2: Overall, the person-level effects are quite similar across the policy models for each cancer type. The younger age group has significantly higher odds of late-stage diagnosis than those age 65+ in all models. Females have significantly higher odds of late-stage CRC diagnosis than males. Blacks, or other races or ethnicities (combined) have significantly higher odds of late-stage diagnoses than whites across all BC models, while only blacks have significantly higher odds of late-stage diagnoses than whites across the CRC models.
County contextual variables. The percentage of the age <65 population who are uninsured is statistically significant at the 95 % level of confidence in 5 out of 6 models, but the effect estimate is very small. Area average distance to closest provider of screening services and its square do not have statistically significant effects in the models. The area level screening rate was positively associated with lower rate of late stage cancer diagnosis for both BC and CRC. In addition, the percent of the area population insured by managed care plans was associated with significantly lower odds of late-stage BC diagnosis, but significantly higher odds in one CRC model.
Higher values of the isolation index reflect greater isolation of the minority group from whites in their residential settings. The isolation index for Asians is associated with significantly higher odds of late stage CRC, and significantly lower odds of late-stage BC diagnosis, relative to cancer patients living in communities with low segregation of Asians. The isolation index for blacks is associated with significantly lower odds of late-stage CRC diagnosis, relative to cancer patients living in communities with low segregation of blacks, in the first CRC model only, and these are not significant predictors in the BC models. By contrast, living in more isolated Hispanic communities has no significant association with late-stage cancer diagnoses.
State insurance regulations. Our analyses found significant interactions in all CRC models and one BC model between age group and state policy, which is the main focus of the paper (Tables 2 and 3). The statistical significance of the age variable, state policy variables and their interactions with age group shown in Tables 2 and 3 cannot be interpreted separately, because the three variables are correlated by construction. Joint tests of the combined effects of age group and state policy and their interaction were statistically significant at greater than 95 % confidence for all three models and both cancer types (p val < 0.05 for joint test of coefficients). To better translate the associations between age groups and state policy, we computed odds ratios reflecting the different combinations of the two variables and plotted them in Fig. 2. The “age 65+ with no state policy in effect” is the reference group in the modeling, represented by the black-and-white striped bars’ height meeting the axis line at ‘1’ in the figure. The under age 65 group is represented by grey and black bars, while the age 65+ are represented by the striped and pink bars. The figure shows that for all three policies, younger people had higher late-stage diagnosis compared to older age groups, with or without policy. For the younger group, living in states where the first two policies were in effect seemed to help reduce the odds of late-stage diagnosis. For the older group, the first two policies also seem mildly beneficial (pink bars shorter than striped bars). For the third policy – greater practice latitude for NPs – for both age groups, the law seems beneficial for BC but not for CRC patients. Perhaps the advice from NPs regarding BC screening is more uncontroversial than such advice for CRC screening, which has serious associated medical risks from the endoscopy procedure.
The Direct Access to Specialist mandate is associated with the most dramatic reduction in the odds of late-stage cancers for younger people as compared to peers in unregulated states (e.g., for CRC, odds ratios are 1.23 vs 1.14 for the younger group in states without and with the mandate, respectively). Findings are similar for the Ban on Financial Incentives mandate, but effects are smaller. For both regulations, the younger group exhibits higher odds of late-stage diagnosis for both cancers, relative to the reference group/seniors, irrespective of policy status.
By contrast, living in states with greater practice latitude for NPs seems to benefit the younger group (1.24 falls to 1.17 in regulated states) and older age group (1.0 falls to 0.94 in regulated states) with BC. For CRC, this policy did not benefit either the younger group (1.12 no policy, 1.21 with policy) or the older group (1.0 no policy and 1.02 with policy).
Robustness: Because it is difficult to ascertain overlapping influences from the policies that may confound attribution of policy effects to particular policies, we ran a combined model. Combining the three policy variables together into a single model did not diminish the statistical significance of the Direct Access to Specialist policy variable. However the Ban on Financial Incentives became statistically weaker and NP practice latitude lost statistical significance. However, the three were significant as a group, and had consistent associations with those noted above.
Estimation Diagnostics: To ascertain the importance of information available in the random intercepts, it is customary to look at the variance components estimated by the model. We find that the variance of the random intercepts at the county and state levels are very small (bottom rows Tables 2 and 3). Two fairly recent papers examining late-stage BC diagnosis in California used the random intercepts multilevel model and found similarly small variance components [25, 8]. We conclude, as they do, that a small variance estimate for the area-level random effects indicates that the contextual factors included in the model do a good job accounting for spatial heterogeneity in the explanatory factors.
This paper provides a comprehensive snapshot across 40 states in the US, based on fully generalizable registry populations, to assess the importance of various predictors of late-stage BC and CRC at first diagnosis for the period 2004–2009. The proportion of late-stage diagnosis is quite a bit higher for CRC (54 %) than for BC (31 %) (Table 1). These findings highlight the value of a new data resource for comprehensive cancer control research .
Separate models are estimated for the person-level odds of late-stage diagnoses for BC or for CRC. For each cancer type, three models are run reflecting three separate state policy regulations. There are some striking similarities in the effect estimates for each cancer type, across the three regulatory models. Person-level effects are quite similar across the regulatory models, and younger age group consistently exhibits higher odds of late stage diagnosis. Women have consistently higher odds of late-stage diagnosis for CRC, as compared to men. A higher area screening rate (for BC, CRC) is associated with significantly lower odds of late-stage diagnosis for both BC and CRC (respectively).
Some interesting differences are apparent across the BC and CRC models. Compared to CRC, the overall incidence of late-stage BC diagnosis is lower, but the racial and ethnic disparities are greater. While blacks and other races or ethnicities (combined) have significantly higher odds of late-stage diagnosis for BC than whites, only blacks have significantly higher odds of late-stage diagnosis for CRC than whites. This is puzzling, and would be a fruitful topic of further research. Perhaps more precise targeting of harder-to-reach minority enclaves is warranted to reduce these disparities.
Other differences across the cancer types are at the community level of influence, where we find several significant factors that contribute to our understanding of these population health outcomes. The percent of the community population insured by managed care plans was associated with significantly lower odds of late-stage BC diagnosis, but was not associated with significantly lower odds of late-stage CRC diagnosis. This dichotomy may reflect spillover effects from managed care which were apparently stronger for BC than CRC screening modalities. This would be expected, given the fact that screening guidelines for CRC were evolving during this period, while BC screening guidelines were well established .
Another interesting difference from community factors across models is the impact of residential segregation. For individuals living in highly segregated Asian communities, odds of late-stage BC diagnosis are significantly lower (than for people not living in such communities) while the opposite is true for CRC. Although it is unclear why, these differences may offer some insights for local cancer control efforts, where targeting certain populations may be of interest.
As shown in Fig. 2, the odds of late-stage diagnosis are considerably higher for the younger (<65) than older group (65+), and consistently so across the three state policy variables. Significant interaction effects between state policy and age group suggest that living in states where two of these policies have been enacted is beneficial for both young and old, and both cancer types. For the third policy, benefits seem evident only for BC diagnoses in both age groups. For the first policy, Direct Access to Specialist without a referral, the benefits in terms of odds reduction are greater for the younger than for the older group.
People in the younger group fall outside normative screening guidelines, and develop cancers for reasons related to greater than average risk factors, including genetic risk. We surmise that the younger group may have a greater need for regulatory protection, as they may be more financially vulnerable, and readily available or affordable insurance coverage may have been less adequate or more restrictive during this period. While we hold constant statistically the area uninsured rate, and find it to be a significant area-level predictor, we cannot know the person’s insurance status. A recent study using a different data source has shown that personal insurance is important to protect against late-stage diagnosis, and that not all insurances are equal in this regard .
We staged this study to end in 2009 so that future research using the USCS database will be able to evaluate ecological effects stemming from the passage of various insurance regulations and their implementation, notably the Affordable Care Act of 2010 and its provisions as they were phased in over time. An interesting future research question would be whether the role of area uninsured becomes less important over time, and whether the young-old age discrepancy and interaction with state regulation becomes less pronounced. This is a fruitful area of future research and the newly available USCS database will be quite valuable in further explaining these disparities and how they are impacted by policy changes.
Centers for disease control and prevention
Fecal occult blood test
National cancer institute
National center for health statistics
National council of state legislatures
Magnetic resonance imaging
Surveillance, epidemiology, and end results
US cancer statistics
National Cancer Institute (NCI). 2015a. “colorectal Cancer Prevention (PDQ®) Available online January 2015: http://www.cancer.gov/types/colorectal/hp/colorectal-prevention-pdq
American Cancer Society (ACS), (2011). “Cancer Facts&Figures”, http://www.cancer.org/research/cancerfactsstatistics/index
Writing Group for the Women's Health Initiative Investigators (WHI). “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial”. JAMA. 2002;288(3):321–33.
American Cancer Society (ACS) 2013. “Colorectal Cancer Facts & Figures 2011-2013”, available online Feb 2015: http://www.cancer.org/Research/CancerFactsFigures/ColorectalCancerFactsFigures/2011-2013-colorectal-cancer-facts-figures.pdf
American Cancer Society (ACS) 2012. “Breast Cancer Facts & Figures 2011-2012”, available online Feb 2015: http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigure/2011-2012-breast-cancer-facts-figures.pdf
National Cancer Institute (NCI). 2015b. The SEER Website as a service of the Surveillance Research Program, NCI . Available online Feb 2015: http://seer.cancer.gov/faststats/selections.php?series = age
Mobley L, Kuo T, Watson L, Brown G. “Geographic disparities in late-stage cancer diagnosis: Multilevel factors and spatial interactions”. Health Place. 2012;18:978–90.
Kuo T, Mobley L, Anselin L. “Geographic Disparities in Late-Stage Breast Cancer Diagnosis in California”. Health Place. 2011;17:327–34.
Henry KA, Sherman R, Farber S, Cockburn M, Goldberg DW, Stroup AM. The joint effects of census tract poverty and geographic access on late-stage breast cancer diagnosis in 10 US States. Health Place. 2013;21:110–21.
Anderson RT, Yang TC, Matthews SA, Camacho F, Kern T, Mackley HB, et al. Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter?”. Health Serv Res. 2014;49(2):546–67.
Ward EM, Fedewa SA, Cokkinides V, Virgo K. The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database. Cancer J. 2010;16(6):614–21.
Wingo P, Jamison P, Hiatt R, Weir H, Gargiullo P, Hutton M, et al. “Building the infrastructure for nationwide cancer surveillance and control - a comparison between The National Program of Cancer Registries(NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States)”. Cancer Causes and Control. 2003;14:175–93.
Centers for Disease Control and Prevention (CDC) (2015). National Program of Cancer Registries, US Cancer Statistics, Available online January 2015: www.cdc.gov/uscs and CDC’s NCHS Research Data Center, available online January 2015 http://www.cdc.gov/rdc
RTI Spatial Impact Factor Database, available online Jun 2015 at https://rtispatialdata.rti.org
National Conference of State Legislators (NCSL). Managed Care State Laws and Regulations, Including Consumer and Provider Protections. http://www.ncsl.org/issues-research/health/managed-care-state-laws.aspx (2010). Accessed Feb 2015.
National Conference of State Legislatures (NCSL). Scope of Practice Legislative Database, 2011–2013. http://www.ncsl.org/issues-research/health/scope-of-practice-legislation-tracking-database.aspx (2013). Accessed Feb 2015.
Kramer M, Hogue C. Is Segregation Bad For Your Health? Epidemiol Rev. 2009;31:178–94.
Palloni A, Arias E. Paradox lost: Explaining the Hispanic adult mortality advantage. Demography. 2004;41:385–415.
Koroukian S, Litaker D, Dor A, Cooper G. Use of Preventive Services by Medicare Fee-for-Service Beneficiaries Does Spillover From Managed Care Matter?”. Med Care. 2005;43(5):445–52.
Mobley L, Subramanian S, Koschinsky J, Frech HE, Clayton L, Anselin L. Managed care and the diffusion of endoscopy in fee-for-service Medicare”. Health Serv Res. 2011;46(6):1905–27.
Goodwin JS, Rounds LR, Loresto Jr FL, Yong-Fan K. “States with the Least Restrictive Regulations Experienced the Largest Increase in Patients Seen by Nurse Practitioners,”. Health Aff. 2013;32(7):1236–43.
Cassidy, A. “Health Policy Brief: Nurse Practitioners and Primary Care,” Health Affairs, October 25, 2012. Available online March 2014: https://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id = 79
Gelman, A. and Hill, J., Data Analysis Using Regression and Multilevel/Hierarchical Models, Cambridge University Press, New York: Ny USA; 2007.
Rabe-Hesketh, S. and Skrondal, A., Multilevel and Longitudinal Modeling Using Stata, Stata Press, Second Edition, College Station: Texas USA; 2008.
Gumpertz ML, Pickle LW, Miller BA, Bell BS. Geographic patterns of advanced breast cancer in Los Angeles: associations with biological and socio- demographic factors (United States)”. Cancer Causes Control. 2006;17:325–39.
CDC’s National Program of Cancer Registries contributed funds to cover the standard RDC fees for researchers conducting analyses under approved research projects. This work was also supported by a National Cancer Institute grant (2R01CA126858). The content is solely the responsibility of the authors and does not necessarily represent the official views of Georgia State University, the University of North Carolina, the National Center for Health Statistics, the National Cancer Institute, orv the National Institutes of Health.
The authors declare that they have no competing interests.
LM and MK together collaborated on all aspects of the analysis, writing, preparation, and submission of this manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Mobley, L.R., Kuo, T. United States Health Policies and Late-stage Breast and colorectal cancer diagnosis: Why such disparities by age?. Health Econ Rev 5, 20 (2015). https://doi.org/10.1186/s13561-015-0058-2
- Late-stage cancer diagnosis
- Cancer control
- Health market regulation
- Age disparity